FIELD: pharmaceutics.
SUBSTANCE: invention relates to a pharmaceutical composition, specifically to a solution for intravenous administration containing as an active substance a Fur-Lys-His-Ala-Asp-Asp heteropeptide, where "Fur" is carboxymethylimidazo[4,5-e]benzo[1,2-c; 3,4-c'] difuroxane, and as auxiliary – citric acid monohydrate, sodium hydroxide to bring pH to 5.35 and water for injections.
EFFECT: invention is proposed for use as an anti-aggregant-inhibitor of GPIIb/IIIa-receptor thrombocytes.
2 cl, 4 dwg, 12 tbl, 8 ex
Title | Year | Author | Number |
---|---|---|---|
PHARMACEUTICAL COMPOSITION IN FORM OF CAPSULES, HAVING NOOTROPIC ACTION | 2019 |
|
RU2725632C1 |
PHARMACEUTICAL COMPOSITION OF ANTITHROMBOTIC ACTION IN SOLID DOSAGE FORM IN THE FORM OF TABLETS | 2019 |
|
RU2696869C1 |
COMBINATION POSSESSING ANTIAGGREGANT, LIPID-REGULATING AND GASTROPROTECTIVE ACTIVITIES, PHARMACEUTICAL COMPOSITION | 2010 |
|
RU2453314C1 |
AGENT SHOWING ANTIAGGREGANT AND ANTITHROMBOGENIC ACTIVITY | 2010 |
|
RU2453312C1 |
RGD-LIKE PEPTIDES | 2009 |
|
RU2396271C1 |
THROMBOCYTE AGGREGATION-INHIBITING HETEROMERIC PEPTIDES BASED ON IMIDAZO[4,5-e]BENZO[1,2-c;3,4-c']DIFUROXANE | 2014 |
|
RU2550223C1 |
2-(3,4-DIHYDROXYPHENYL)-9-DIETHYLAMINOETHYLIMIDAZO[1,2-a]BENZIMIDAZOLE DIHYDROBROMIDE AND BASED ON IT PHARMACEUTICAL COMPOSITION | 2008 |
|
RU2391979C2 |
AGENT EXHIBITING ANTIPLATELET AND ANTICOAGULANT ACTIVITY | 2014 |
|
RU2573379C1 |
ANTIPLATELET AGENT | 2017 |
|
RU2647366C1 |
AGENT WITH ANTIPLATELET AND ANTICOAGULANT ACTIVITY | 2015 |
|
RU2601407C1 |
Authors
Dates
2019-12-13—Published
2019-08-27—Filed